Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)
Longitudinal Assessment of Amyloid Positron Emission Tomography (PET), Fludeoxyglucose F18 (FDG) PET, Tau PET, Magnetic Resonance Imaging (MRI), and Blood Spot Ribonucleic Acid (RNA) in Down Syndrome Individuals With and Without Alzheimer's Dementia and Normal Controls
Sponsor: Banner Alzheimer's Institute, Phoenix
A NA clinical study on Alzheimer's Dementia and Down Syndrome, this trial is completed. The trial is conducted by Banner Alzheimer's Institute, Phoenix and has accumulated 7 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Nov 2019 — Jan 2021 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jul 2019 — Nov 2019 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Banner Alzheimer's Institute, Phoenix
- St. Joseph's Hospital and Medical Center, Phoenix
- Translational Genomics Research Institute (TGEN), Phoenix
For direct contact, visit the study record on ClinicalTrials.gov .